Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
β-Hydroxybutyrate as a Predictive Biomarker for SCRT Followed by Chemotherapy +/- PD-1 Inhibitor in Locally Advanced Rectal Cancer
NCT07847229Phase 2Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in rectal cancer (4 arms). Primary endpoint: Complete Response Rate at 12 months. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07847229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07847229.